Translational Partnerships and New Indications - Device Portal

Application ProcessSteps necessary for applying to New Market Indications funding opportunities
Application process for New Market Indications


The following table shows a list of companies that have signed a Memorandum of Understanding (MOU) with NIH to participate in the Translational Partnerships and New Indications component of the SPARC program. The table provides basic information on the devices and support that each company will make available for current and future applicants seeking NIH funding. Interested potential applicants can obtain further information on devices by contacting the Company Contact listed in the table below. Since we envision multiple funding opportunities, we will continue to partner with additional companies beyond the initial set of funding announcements. Companies that are potentially interested in participating should contact Siavash Vaziri


Please check this site in the future for additional devices being made available as new partnerships are formed. 


Devices Table



Application / Original Indication

Regulatory Status


Device information and company support

Company Contact


Utah arrays (NeuroPortTM and slanted arrays)

Stimulation/recording for cortical and peripheral applications

510(k) and IDE

Pneumatic electrode inserter system, NeuroPort data acquisition system

Device Information

Dr. Robert Franklin - Engineering Manager

Boston Scientific

PrecisionTMstimulation systems

Spinal cord stimulation


Various percutaneous and surgical paddle stimulation leads

Device Information

Dr. Juan Hincapie - Principal R&D

VerciseTM stimulation systems

Deep brain stimulation


DBS Guide software, DBS standard or directional leads


Brain InterchangeR and AirRayR Electrode

Implantable system for chronic open and closed loop interaction

In process

Hermetic Encapsulation technology

Device Information

Dr. Jörn Rickert  – CEO



Baroreflex activation therapy for resistant hypertension and heart failure


Electrical stimulation and data acquisition hardware and software

Device Information

Dr. Seth Wilks - Principal Research Scientist

ImThera Medical


Obstructive sleep apnea


6-contact cuff electrode, Clinical Manager software

Device Information

Mr. Marcelo Lima - CEO


Activa RC+S

General purpose research system (similar in capability to Activa RC/PC used in DBS)


Nexus (-D and -E) Algorithm Development Toolkit, Nexus-I Research System for Intellis neurostimulator, Vectris MRI leads, Reveal LINQ Cardiac Monitor

Device Information

Intellis Information

Dr. Heather Orser - Senior Engineering Manager

Enterra II

Gastric electrical stimulation



Spinal cord neuromodulation


InterStim II

Sacral neuromodulation



Spinal cord neuromodulation



Various electrode technologies

General purpose neural interface technology

In process

Conformal arrays, STIM-GRID high density arrays, Precision electrodes, Multi-contact cuffs

Device Information

Dr. Bryan McLaughlin - President


Conventional and high-definition thin-film electrodes

General purpose neural interface technology

In process

External neural recording and stimulation systems

Device Information

Dr. Daryl Kipke - President

Nexeon MedSystems


General purpose research system

In process

3-contact helical cuff lead and 4-contact percutaneous lead

Device Information

Mr. Will Rosellini - CEO


LinkTM and Link-STM

Stimulation/recording for neurophysiology and neuroprostheses research

In process

Grapevine Neural Interface System, 3D printing of flexible electrodes, software support

Device Information

Dr. Daniel McDonnall - President and Vice President of Research


Freedom Stimulator System

Peripheral nerve or spinal cord wireless neurostimulators for pain management


External transmitter for power

Device Information

Ms. Laura Tyler Perryman - Chairman and CEO

Template Agreements

The following template documents may be used to streamline creating partnerships between investigators and device companies. Investigators are strongly encouraged to consult early with their institutional technology transfer or sponsored research office in order to confirm that the terms and conditions of the CDA and CRA for the selected device are at or near acceptable to their institution.

       CDA - Confidential Disclosure Agreement
This template document can be signed by academic researchers to allow confidential discussions of proprietary details with a given company regarding the capabilities of a device prior to submitting SPARC funding announcement applications. In some cases the template language may be used “as is” whereas in other cases it may be a starting point for discussions.

       CRA - Collaborative Research Agreement
This is a template document to be used for agreements between device manufacturers and academic research institutions to form partnerships for submission of SPARC funding announcement applications. The goal of this document is to provide standardized terms covering essential components of such agreements (e.g., intellectual property, data and publications, reporting requirements, etc.). In some cases the template language may be used “as is” whereas in other cases it may be a starting point for discussions. 

       MOU - Memorandum of Understanding
The purpose of this document is to describe the nature of the signatory company's agreement to participate in the program. The document goes over the process under which Collaborative Research Agreements will be reached with academic researchers wishing to use the company's device(s) prior to receiving NIH funding through the SPARC program. Each signatory company has provided a description of the materials and support it is willing to make available for this purpose and has agreed to use the template Collaborative Research Agreement for partnering with research institutions for this program. 

This page last reviewed on July 31, 2018